color eas concern lt ep growth
organ growth vs cs estimate plu addit non-op fx
help drive beat vs estim help boost confid
mdt abil execut top line addit investor concern
appear eas dip ep growth compani
long-term growth target first rais manag earli januari
driven mostli tax fx continu view mdt organ
sale growth sustain expect non-op impact tax fx
ep albeit signific least partial off-set non-op
financi lever see littl impact mdt intermedi long-term
growth potenti reiter outperform rate rais
target driven primarili increas share repurchas
pipelin come focu drive increas growth
signific recent upcom product launch includ tavr low-risk
data label expans mazor stealth robot surgeri system
spine minim hybrid close loop insulin deliveri system
micra av leadless pacemak expand indic
upcom event catalyst management brief crt dc result
low-risk tavr wrap-it tyrx trial
valuat target price previous base
ebitda multipl unch ebitda bil unch risk
includ key product delay failur progress long-term goal growth
margin potenti new litig regulatori qualiti issu
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
mariu zoican univers toronto rotman school manag februari
medtron plc global manufactur provid medic
devic equip area cardiac rhythm manag
vascular intervent structur valvular diseas spinal
disord neuromodul surgic equip diabet
price feb rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
one-year valuat scenario base
ev/ebitda ebitda
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
mariu zoican univers toronto rotman school manag februari
addit detail takeaway
manag emphas strength mdt product pipelin
ceo omar ishrak highlight number recent upcom product launch
remark includ disrupt new product robot surgeri mazor stealth leadless
pacemak micra av stroke riptid react solitair structur heart
evolut pro low-risk tavr result indic intrepid mitral valv replac
system diabet hybrid closed-loop insulin pump select
notabl pipelin product timelin estim size respect target market
summar
figur medtron near- intermediate-term product pipelin
integr robot navig platform
design retriev thrombu restor blood flow patient
clot retriev system acut ischem stroke
end
sens technolog closed-loop deep brain stimul system
sacral nerv micro stimul bladder control full-bodi
transcathet aortic valv replac treatment
symptomat sever aortic stenosi low-risk patient
reduc size tavr valv vs current treatment
insert cardiac monitor system diagnosi cardiac
arrhythmia stroke
leadless pacemak treatment bradycardia expand
indic appli pacemak market
new convent crt-d product famili base polari
transcathet mitral valv replac treatment mitral
renal denerv system treatment drug-resist
monitor cerebral/somatic-oximetri help reduc post-operative
enabl gi tract visual small dispos capsul
advanc hybrid close loop type insulin system bluetooth
person close loop system adapt continu user
next-gen sensor reduc need calibr smaller longer-
mariu zoican univers toronto rotman school manag februari
perform major busi line
cvg bil mil y/i cc organ
 heart failur sale bil mil declin organ
perform led mid-teen declin heart failur primarili due mid-
declin lvad result market share loss chang heart transplant
guidelin partial off-set mid-singl digit growth arrhythmia manag
led growth tyrx absorb antibacteri envelop mid-teen growth
af solut pacer grew mid-singl digit driven strength micra azur
icd grew low-singl digit compani schedul present result
wrap-it trial evalu abil tyrx envelop reduc cardiac implant
electron devic infect march confer servic solut also
declin low- due revenu recognit chang larg va order product
coronari structur heart sale mil mil increas organ
perform led mid-teen tavr growth ou
compani schedul present low-risk clinic trial result march
confer coronari growth flat quarter driven mid-teen growth guid
cathet low-doubl digit growth coronari balloon partial off-set low-singl
digit declin drug-elut stent
aortic peripher venou sale mil mil increas organ
perform led mid-teen growth endoven closur system
pact admir dcb thorac stent graft system grew high-singl digit
manag expect cvg growth similar growth
full year
mitg bil y/i cc organ
surgic innov sale bil mil increas organ
perform led high-singl digit growth advanc surgic low-
doubl digit growth advanc high-singl digit growth advanc stapl
genera surgic growth mid-singl digit driven strength wound closur
respiratori gastrointestin renal sale mil mil increas
organ perform led mid-teen growth renal high-
singl digit growth respiratori gastrointestin solut grew mid-singl digit
manag expect mitg grow /- growth full
led high-teen growth
rtg bil mil y/i cc organ
brain therapi sale mil mil increas organ
neurosurgeri
neurovascular neurosurgeri strength driven strong demand stealthstat
mazor o-arm imag system
pain therapi sale mil mil increas organ perform
driven high-singl growth spinal cord stimul mid-singl digit
growth intervent pain
spine sale mil mil declin flat organ perform along
capit equip use spine surgeri part brain therapi grew
spine grew quarter manag expect futur growth spine implant
driven strong capit equip sale
mariu zoican univers toronto rotman school manag februari
specialti therapi sale mil mil increas organ
perform driven mid-teen growth transform solut mid-
singl digit growth ent
manag expect mitg grow growth full year
diabet mil mil y/i cc organ
advanc insulin manag grew mid-singl digit driven insulin pump perform
europ latin america china growth
integr cgm led increas penetr higher attach rate insulin
pump sale face difficult comp sale backlog address prior year
upon reach full sensor manufactur capac emerg grew
driven third consecut year tripl digit growth guardian connect cgm
manag expect diabet flat low-mid teen growth full
 oper margin bp estim
bottom line sale net cog lower sg lower
lower tax deliv ep fx benefit deliv beat ep
gross margin bp y/i bp estim
compani rais bottom-end organ sale guidanc
bottom-lin also slightli rais ep guidanc
compar factset consensu compani also rais
guidanc bil bil manag yet provid
guidanc compani reiter expect point expect
tax rate expect modest headwind fx well
compani express comfort current consensu ep estim
time call per share factset
estimate
ep
sale
sale
sale
sale
mariu zoican univers toronto rotman school manag figur revenu summari actual vs estim
estimate
mariu zoican univers toronto rotman school manag februari
chang model
rais estim sale mil bil rais
ep estim in-lin revis guidanc beyond
rais sale estim driven primarili chang
make modest chang ep
figur chang model
mariu zoican univers toronto rotman school manag februari
target price previous base ebitda multipl unch
ebitda bil unch risk includ key product delay failur progress
long-term goal growth margin potenti new litig regulatori
mariu zoican univers toronto rotman school manag compani mention price
